Skip to main content
OpenTrials

Clinical trial condition

Blood Protein Disorders

Explore clinical trials studying Blood Protein Disorders. Study availability and eligibility vary by location and protocol.

3,042 public trials 567 recruiting studies
Refine in advanced search Browse all conditions

Blood Protein Disorders trial results

Completed

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

NCT01056276

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Los Robles Hospital and Medical Center Thousand Oaks, California, United States
  • Florida Cancer Specialists Fort Myers, Florida, United States
  • Hematology Oncology Clinic, LLP Baton Rouge, Louisiana, United States
  • Center for Cancer and Blood Disorders Bethesda, Maryland, United States
View all 13 locations
View Trial Details
Completed

A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma

NCT02072863

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Department of Clinical Therapeutics, University of Athens Athens, Attica, Greece
  • Ospedale Oncologico Regionale Rionero in Vulture, Potenza, Italy
  • Azienda Ospedaliera Universitaria S Martino Genova, Italy
  • AOU Maggiore della Carita, SCDU Heamatology Novara, Italy
View Trial Details
Completed

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

NCT01949532

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +27 more
Locations
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • North Shore-LIJ Health System/Center for Advanced Medicine - North Shore University Hospital Lake Success, New York, United States
  • Gabrail Cancer Center Canton, Ohio, United States
  • Vanderbilt-Ingram Cancer Center, Henry-Joyce Cancer Clinic Nashville, Tennessee, United States
View all 13 locations
View Trial Details
Completed

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

NCT00530816

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Scottsdale Scottsdale, Arizona, United States
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • Therapeutic Research Institute of Orange County Laguna Hills, California, United States
  • Rocky Mountain Blood and Marrow Transplant Program Denver, Colorado, United States
View all 30 locations
View Trial Details
Completed

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

NCT00721734

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Female Urogenital Diseases, +19 more
Locations
  • University of California- San Francisco San Francisco, California, United States
  • University of Maryland Medical Center Baltimore, Maryland, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View Trial Details
Completed

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

NCT00150462

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +20 more
Locations
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Weil Medical College of Cornell University New York, United States
View Trial Details

Related conditions